| Identification | Back Directory | [Name]
FAPI-4 | [CAS]
2374782-02-0 | [Synonyms]
FAPI
FAPI-4
187366
FAPI04
(S)-2,2’,2’’-[10-[2-[4-[3-[[4-[[2-(2-Cyano-4,4-difluoro-1-pyrrolidinyl)-2-oxoethyl]carbamoyl]-6-quinolyl]oxy]propyl]-1-piperazinyl]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetic Acid
(S)-2,2',2''-(10-(2-(4-(3-((4-((2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-6-yl)oxy)propyl)piperazin-1-yl)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid | [Molecular Formula]
C40H54F2N10O10 | [MDL Number]
MFCD32067986 | [MOL File]
2374782-02-0.mol | [Molecular Weight]
872.93 |
| Chemical Properties | Back Directory | [Boiling point ]
1144.1±65.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 100 mg/mL (114.56 mM) | [form ]
Solid | [pka]
1.83±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
FAPI-4 is a substituted pyrrolidinyloxoethyl quinolinecarboxamides and one type of theranostic ligand for fibroblast activation protein (FAP). FAPI-4 is a FAP inhibitor (FAPI) and has been studied for its pharmaceutical properties in the diagnose or treatment of diseases driven by the overexpression of FAPs. | [in vivo]
FAPI-4 (Intravenous injection; 30 nmol per mouse; once) shows excellent tumor uptake in BALB/c nu/nu mice[2]. | Animal Model: | 8-week-old BALB/c nu/nu mice inoculated with HT-1080-FAP cells[2] | | Dosage: | 30 nmol per mouse | | Administration: | Intravenous injection; 30 nmol per mouse; once | | Result: | Revealed the high overall tumor uptake (9.44%ID/g 4 h after injection). |
| [storage]
Store at -20°C |
|
| Company Name: |
Tetranov Biopharm
|
| Tel: |
13526569071 |
| Website: |
http://www.leadmedpharm.com/index.html |
| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0510-83588313-811 18800520310; |
| Website: |
https://www.jiehuapharma.com/ |
|